PPARG and familial pancreatic carcinoma: Vitale et al. [85] showed that, in pancreatic cancer cells, PPAR-γ agonist (troglitazone, TGZ) counteracts STAT3 protein potentiating the anticancer effects of IFN-β through the induction of cell cycle perturbations and the occurrence of autophagy cell death in pancreatic cancer cells.